LATEST MEDICAL CANNABIS STOCK NEWS
The successful import demonstrates the strength of the IM Cannabis global supply chain and business model
TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / January 19, 2022 / IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC)(NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany is pleased to announce that Focus Medical Herbs Ltd. ("Focus... Read more
Martha Stewart CBD Launches its First-Ever Category Expansion with New Line of CBD Wellness Topicals
New Super Strength CBD Cream, Sleep Science CBD Cream and Daily De-Stress CBD Cream Add to Martha's Wellness Portfolio
SMITHS FALLS, ON and NEW YORK, Jan. 19, 2022 /CNW/ - Today, Martha Stewart CBD unveiled Martha Stewart CBD Wellness Topicals, marking the brand's first-ever category expansion in its growing CBD portfolio. Martha Stewart CBD provides consumers with an easy way to manage their... Read more
Leading CBD Drinks Brand Aligns with USA's Fastest Growing Sport, Keeping Players Refreshed and Revitalized
1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF) (OTCQB:TGIFF), a Nevada-focused cannabis consumer packaged goods company, is pleased to announce that Day One Beverages, Inc. ("Day One") has been named the exclusive and "Official CBD Partner of USA Pickleball", America's fastest growing sport, for... Read more
AREV LIFE SCIENCES GLOBAL CORP. (CSE:AREV) (CNSX:AREV.CN) (OTC:AREVF) (“AREV” or the “Company”) is pleased to announce a recent study by Richard Van Breeman PhD, a member of AREV’s Scientific Advisory Board (SAB), along with collaborators at Oregon State University’s (OSU) College of Pharmacy, the Linus Pauling Institute and OSU’s Global Hemp Innovation Center, published in the January edition of the Journal of... Read more
Puration, Inc. (OTC Pink: PURA) today published a 2022 strategic management overview of the company’s plan for an anticipated $1 million in revenue with the potential to reach $10 million in revenue this year. The overview published today will be followed up over the next several weeks with additional management presentations covering more detail on each of the major overview components highlighted in the presentation... Read more
WEED is exploring possibility of building out our 43 acre Sugar Hill Golf Course in Westfield, NY into:
The 4 Winds Luxury Condos & Villas Resort- Cannabis friendly!
WEED, Inc. (OTCQB:BUDZ) ("WEED" or the "Company"), a cannabis and hemp bioresearch company based in the USA, announced in December that it completed the purchase of the Sugar Hill Golf Course in Westfield, New York making the Final Payment of ~$250,000... Read more
Item 9 Labs Corp. (OTCQX: INLB) (the "Company")—a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products—today reported operating and financial results for the 12 months ended September 30, 2021, the Company's fiscal year 2021 ("FY2021"). Item 9 Labs Corp. management will be hosting an earnings results call today, January 18, at 2:00... Read more
SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that it has entered into an agreement with two clinical sites: Hannover Medical School in Hannover, Germany, and Tel-Aviv Sourasky Medical School, in Tel-Aviv, Israel, to further its Phase IIb clinical study... Read more
Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announces that, further to its press release dated December 23, 2021, it has closed its acquisition (the "Acquisition") of Arizona-based Foundations for Change, Inc. ("Foundations"), a mental health practice specialized in ketamine-assisted psychotherapy.
"We're thrilled to welcome... Read more
1933 Industries Signs Binding Letter of Intent to Acquire Beverage Company Day One
1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF) (OTCQB:TGIFF), a Nevada-focused cannabis consumer packaged goods company, is pleased to announce that it has entered into a binding Letter of Intent ("LOI") to acquire 100% of all of the authorized and issued shares of Day One Beverages, Inc. ("Day One"), a disruptive... Read more
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has inaugurated its first and new drug research and development lab at Biohouse Labs at Hadassah Medical Center in Jerusalem to accelerate the Company's liposome Platform Technology (LPT) development. The Company's development program is focused on improving and optimizing LPT characterization methods... Read more
Oren Shuster remains Chief Executive Officer and Director of IM Cannabis Corp.; other managerial changes include the promotion of Yael Harrosh to Chief Legal and Operations Officer of IM Cannabis Corp.
IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC) (NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany today announced the appointment of... Read more
Novamind Inc. (CSE:NM) (OTCQB:NVMDF) (FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced it will host a phase I randomized clinical trial for adults with opioid use disorder. The study will investigate the safety and efficacy of ketamine-assisted psychotherapy combined with Mindfulness-Oriented Recovery Enhancement therapy (the "MORE+KAP Clinical... Read more
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce a second amendment (the "Amendment") to the research and license agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. ("Yissum") for the performance of studies evaluating the efficacy of its CBD-Loaded Liposome Platform Technology (LPT) in treating dogs.
The Amendment... Read more
Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary Kannaway® has opened a new office and warehouse in Warsaw, Poland.
The new 7,771 square foot warehouse is strategically positioned near the... Read more
PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of specialty ketamine prescription-based products, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted an investigator-initiated investigational new drug ("IND") application to proceed with a Phase 2 clinical trial (the “Study”) evaluating... Read more
SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company"), announced that it has begun to examine the possibility of including psychedelic compounds as potential drug candidates for its intellectual property portfolio.
Despite being heavily regulated around the world, psychedelics have... Read more
CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (“CBD”) products, today announced the launch of +PlusCBD™ Pain Relief topicals: four unique Over-the-Counter (“OTC”) products formulated to pinpoint sources of minor pain and aches using active ingredients including warming camphor and cooling... Read more
Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has closed the sale of its last remaining cannabis facility, completing a transition to the biopharmaceutical industry.
"This is a landmark event for Gb Sciences," said Chairman and CEO John Poss. "We have emerged from this sale as a pure-play biopharmaceutical research and development company. With an... Read more
Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has entered into a binding term sheet to sell to FlowerPod LLC all patents and related intellectual property pertaining to Emerald's vaporizer cannabis puck concept in exchange for US$1 million in cash and a US$500,000 one-year interest-bearing secured promissory note. As part of the transaction, Emerald will transfer its ownership interest back to... Read more
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the first quarter ended November 30, 2021 (“Q1 Fiscal 2022”).
“Our record-breaking results in the first quarter of Fiscal 2022 are a testament to our successful strategy to create innovative, high-quality products... Read more
The agreement is anticipated to contribute to correcting the opioid crisis in Canada and serve as a foundation for both companies to potentially expand into new verticals in the future
Levitee Labs and Canntab Therapeutics have executed a services agreement resulting in Levitee Labs informing patients about the Canntab portfolio of therapeutics
Levitee Labs will offer the entire Canntab product lineup throughout all its... Read more
Net Revenue Increased ~20% to $155 Million from the Prior Year Quarter
Net Income Improved $95 Million to $6 Million from the Prior Year Quarter
Adjusted EBITDA of $13.8 Million, 11th Consecutive Quarter of Positive Adjusted EBITDA
Achieved $70 Million in Cost Synergies To Date; On-Track to Exceed Original Plan of $80 Million Ahead of Schedule and to Generate Additional $20 Million of Synergies in Fiscal... Read more
Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to provide an update on its recent product deliveries for Ontario and Australia.
On January 7, 2022 Canntab completed its first shipment of 5 mg THC tablets to the Ontario Cannabis... Read more
SciSparc Ltd. (NASDAQ: SPRC) (the "Company"), a clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that The Israeli Medical Center for Alzheimer's has recruited the first patient to participate in the Company's Phase IIa clinical trial that will evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer's... Read more
Novamind Inc. (CSE:NM) (OTCQB:NVMDF) (FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today unveiled its clinic design concept (the "Design Concept") to accommodate the unique requirements of psychedelic-assisted psychotherapy. The Design Concept will launch first in Novamind's Park City, Utah location, and later across Novamind's de novo clinics. Select design... Read more
The inaugural report details the Company's commitment to building a responsible and sustainable organization defined by purpose
Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC) today announced the release of its Environmental, Social, and Governance (ESG) Report ("the Report") for calendar year 2020, as well as qualitative details on some key activities that occurred in 2021. The... Read more
CV Sciences, Inc. (OTCQB: CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced a major new distribution agreement with GNC. Beginning in early 2022, consumers will be able to purchase the Company’s top selling ingestible products under the +PlusCBD™ brand in 770 GNC locations. The initial product... Read more
Company plans to focus development of Zygel™ in FXS, ASD and 22q
Company plans to initiate Phase 3 trial with Zygel in ASD in the second half of 2022
Zynerba to hold conference call tomorrow, January 5, 2022 at 9:00 a.m. ET
Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric... Read more
Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary Kannaway® Japan had its best revenue month in the Company’s history in December 2021.
According to Research and Markets, the global CBD oil market is... Read more
Item 9 Labs Corp. (OTCQX: INLB) (the "Company")—a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products—announced today that Eric C. Kutscher, Pharm. D., M.B.A., F.A.S.H.P., and Lawrence X. Taylor have been appointed to its Board of Directors.
"Eric and Lawrence have vastly different backgrounds that will enrich our foundation across several... Read more
SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), marks today one of the Company's most important milestones to date - the U.S. Patent and Trademark Office has granted it a new patent - U.S. Patent No. 11,207,290, titled combinations of cannabinoids and n-acylethanolamines... Read more
Starting January 1st, 2022, every insurance provider in Colombia, is now mandated to cover the costs of high and low THC medical cannabis prescriptions
Significantly improves the current insurance coverage process, simplifying the procedure and reducing approval times for patients to obtain insurance coverage across the country
Colombia has upwards of 6 million potential patients for medical cannabis products (Source:... Read more
• Believed to be the largest shipment of medical cannabis to Israel to-date • Aurora continues to advance strategic leadership in the global cannabinoid industry
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the delivery of a cannabis shipment worth approximately C$10 million - the company's largest ever... Read more
Second published study to demonstrate the potential therapeutic utility and mechanism of action of KETABET™ (patented combination of ketamine and betaine) in models of depression
Repeated use of KETABET™ exhibits potential protective and reversing effects on ketamine-elicited psychotomimetic behaviors and cognitive impairments
Supports clinical initiatives as a potential next generation ketamine treatment for mental... Read more
Newly created directorship to be filled by Chitwant Kohli, Senior Financial Executive
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the appointment of Chitwant Kohli to the Company's Board of Directors (the "Board"), effective today. This is a newly added... Read more
Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest and most experienced cultivators, manufacturers and providers of cannabis products in the U.S., announced today the opening of Cannabist Virginia Beach, its fourth dispensary in the Commonwealth and 23rd Cannabist nationwide, located at 535 N Birdneck Road.
“Virginia’s demand for high quality... Read more
1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF) (OTCQB:TGIFF), a Nevada-focused cannabis consumer packaged goods company, is pleased to announce its first quarter ("Q1 2022") financial results for the three months ended October 31, 2021. All amounts expressed are in Canadian dollars.
Financial statements are prepared in accordance with International Financial Reporting Standards (IFRS). Detailed... Read more
Lotus Ventures Inc. (CSE: J) (OTC: LTTSF) (“Lotus” or the “Company”), a trusted cannabis producer in Canada is pleased to report its Fiscal 2021 full year results and a second consecutive year reporting a profit for the year ended August 31, 2021.
Full year revenue increased to $5.4 million up 18 percent compared to the prior year.
Fourth quarter revenue of $1.2 million, a decrease compared to the prior... Read more
SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today provides updates regarding its activities in 2021.
Itzhak Shrem, Chairman of the board of SciSparc, said, "We are excited to conclude a very eventful and successful year. We reached several important milestones,... Read more
Entourage Health Corp. (formerly WeedMD Inc.) (TSX-V:ENTG) (OTCQX:ETRGF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products and brands, announced today it has amended its existing credit facility (“Credit Facility”) with an affiliate of the LiUNA Pension Fund of Central and Eastern Canada (“LPF”) to add an additional $20 million in non-dilutive... Read more
AREV LIFE SCIENCES GLOBAL CORP. (CSE:AREV) (CNSX:AREV.CN) (OTC:AREVF) (“AREV” or the “Company”) is pleased to announce the appointment of Allan Echino as Director effective December 21, 2021 and Denby Greenslade as interim Chief Financial Officer (“CFO”), effective December 17, 2021.
Allan Echino began his entrepreneurial experience as a youngster, working in the family business in Kamloops, BC. As well as... Read more
Novamind Inc. (CSE:NM) (OTCQB:NVMDF) (FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, has signed a definitive agreement (the "Agreement") to acquire Arizona-based Foundations for Change, PLC ("Foundations"), a mental health practice specialized in ketamine-assisted psychotherapy, from its sole stockholder, Jeff Edelman, (the "Seller"). The transaction (the... Read more
Love Hemp Group PLC ("Love Hemp" or the "Company") (AQSE:LIFE) (OTCQB:WRHLF), the brand-led consumer goods company focussed on CBD health and wellness solutions, is pleased to announce it has launched, on a trial basis, with Deliveroo, the on-demand delivery service.
A Love Hemp virtual store with the Company's full range of products is now live on Deliveroo. This initial launch is considered a trial by the Company to gauge... Read more
CannAmerica Brands Corp. (CSE:CANA) (CNSX:CANA.CN) (OTC:CNNXF) ("CannAmerica" or the "Company”) further to the Company’s news release dated December 16, 2021, wherein the Company announced the execution of the Purchase Agreement (the “Agreement”) of CannAmerica’s Colorado licensee, Arsenal Oils and Extracts, LLC (“Arsenal”) and the execution of a Management Agreement by the Company’s wholly owned US subsidiary... Read more
As an early investor in biosynthesis, Organigram Holdings Inc. (NASDAQ: OGI), (TSX: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, and Hyasynth Biologicals Inc. (“Hyasynth”) a private biotechnology company and pioneer in the field of cannabinoid science and biosynthesis are pleased to announce that Organigram has acquired an additional $2.5... Read more
All amounts expressed in Canadian dollars unless otherwise noted
PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has plans to issue up to 15,000 debenture units (each a "Unit") in a non-brokered private placement (the... Read more
Organigram Holdings Inc. (TSX: OGI and NASDAQ: OGI), the parent company of Organigram Inc. (collectively “Organigram” or the “Company”), a leading licensed producer of cannabis, is pleased to announce it has acquired all of the issued and outstanding shares of Laurentian Organic Inc. (“Laurentian”), in a cash and share transaction for aggregate consideration of $36 million, plus earnout consideration (the... Read more
VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) ("VIVO" or the "Company") is pleased to announce the appointment of Shai Altman and Glen Huber to the board of directors of the Company (the "Board"), effective immediately.
"I am very pleased to welcome Mr. Altman and Mr. Huber to the Board of Directors," said Ray Laflamme, Chairman of the Board and Chief Executive Officer of VIVO. "Both Mr. Huber and Mr. Altman have strong... Read more
Strong cash balance and continued reduction of convertible debt to less than $500K.
Opportunities for optimization of the operating strategy between Australia and Canada as the Canadian Drug Establishment Licence (DEL) unlocks many manufacturing and supply chain pathways. These pathways will reduce infrastructure cost, improve delivery times, and increase customer satisfaction.
Delivery to five international medical... Read more
Focused on becoming a leader in the development and commercialization of specialty ketamine prescription-based products
Expected milestones for 2022 include initiating Phase 3 clinical study for ketamine to treat Parkinson’s disease (KETLID); completing Phase 2 clinical study for ketamine to treat ALS (KETALS); completing observational study with ketamine and betaine for depression and pain (KETABET); initiating Phase 2... Read more